Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil H Bander

Showing results (41-50 of 85) with videos related to

Pageof 9
Sort By:
Frontiers in Oncology|August 30, 2013
Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen monoclonal antibody j591 in men with metastatic castration-resistant prostate cancerScott T Tagawa, Naveed H Akhtar, Anastasia Nikolopoulou, et al.
Lab on a Chip|December 22, 2009
Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibodyJason P Gleghorn, Erica D Pratt, Denise Denning, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 6, 2005
Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?Shankar Vallabhajosula, Ichei Kuji, Klaus A Hamacher, et al.
The Journal of Urology|October 9, 2003
Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigenNeil H Bander, Edouard J Trabulsi, Lale Kostakoglu, et al.
Cancer Metastasis Reviews|January 13, 2006
Antibody-based therapeutics: focus on prostate cancerJeffrey S Ross, Karen E Gray, Iain J Webb, et al.
International Journal of Oncology|October 4, 2007
Interaction of prostate specific membrane antigen with clathrin and the adaptor protein complex-2Oscar B Goodman, Sonali P Barwe, Brigitte Ritter, et al.
The Prostate|January 24, 2025
Baseline Imaging Derived Factors of Response Following [225Ac]Ac-J591 Therapy in Metastatic Castration-Resistant Prostate Cancer: A Lesion Level AnalysisJudith Stangl-Kremser, Andres Ricaurte-Fajardo, Sandra Huicochea Castellanos, et al.
Nanomedicine (London, England)|October 19, 2012
Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticlesPedro M Valencia, Eric M Pridgen, Brian Perea, et al.
Nanomedicine (London, England)|April 17, 2010
ChemoRad nanoparticles: a novel multifunctional nanoparticle platform for targeted delivery of concurrent chemoradiationAndrew Z Wang, Kai Yuet, Liangfang Zhang, et al.
The Prostate|July 10, 2023
Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic castration-resistant prostate cancer receiving prostate-specific membrane antigen targeted radionuclide therapyJudith Stangl-Kremser, Michael Sun, Benedict Ho, et al.
Pageof 9

Showing results (41-50 of 85) with videos related to

Sort By:
Pageof 9
Frontiers in Oncology|August 30, 2013
Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen monoclonal antibody j591 in men with metastatic castration-resistant prostate cancerScott T Tagawa, Naveed H Akhtar, Anastasia Nikolopoulou, et al.
Lab on a Chip|December 22, 2009
Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibodyJason P Gleghorn, Erica D Pratt, Denise Denning, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 6, 2005
Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?Shankar Vallabhajosula, Ichei Kuji, Klaus A Hamacher, et al.
The Journal of Urology|October 9, 2003
Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigenNeil H Bander, Edouard J Trabulsi, Lale Kostakoglu, et al.
Cancer Metastasis Reviews|January 13, 2006
Antibody-based therapeutics: focus on prostate cancerJeffrey S Ross, Karen E Gray, Iain J Webb, et al.
International Journal of Oncology|October 4, 2007
Interaction of prostate specific membrane antigen with clathrin and the adaptor protein complex-2Oscar B Goodman, Sonali P Barwe, Brigitte Ritter, et al.
The Prostate|January 24, 2025
Baseline Imaging Derived Factors of Response Following [225Ac]Ac-J591 Therapy in Metastatic Castration-Resistant Prostate Cancer: A Lesion Level AnalysisJudith Stangl-Kremser, Andres Ricaurte-Fajardo, Sandra Huicochea Castellanos, et al.
Nanomedicine (London, England)|October 19, 2012
Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticlesPedro M Valencia, Eric M Pridgen, Brian Perea, et al.
Nanomedicine (London, England)|April 17, 2010
ChemoRad nanoparticles: a novel multifunctional nanoparticle platform for targeted delivery of concurrent chemoradiationAndrew Z Wang, Kai Yuet, Liangfang Zhang, et al.
The Prostate|July 10, 2023
Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic castration-resistant prostate cancer receiving prostate-specific membrane antigen targeted radionuclide therapyJudith Stangl-Kremser, Michael Sun, Benedict Ho, et al.
Pageof 9